[SCHEDULE 13G] NeoGenomics, Inc. SEC Filing
Neogenomics, Inc. Schedule 13G discloses that First Light Asset Management, LLC beneficially holds 9,544,749 shares of Neogenomics common stock (about 7.39% of the class). Mathew P. Arens is reported as beneficial owner of 9,784,749 shares (about 7.57%), which reflects his control of the manager plus 100,000 shares held directly and additional shares held jointly. The filing is submitted under Rule 13d-1(b), indicating these holdings are reported as passive and not intended to change or influence control of the issuer. The filing includes a joint filing agreement and identifies the reporting persons' business address.
Neogenomics, Inc. — Il Schedule 13G riporta che First Light Asset Management, LLC detiene in via beneficiaria 9.544.749 azioni del capitale sociale ordinario di Neogenomics (circa 7,39% della classe). Mathew P. Arens risulta titolare beneficiario di 9.784.749 azioni (circa 7,57%), cifra che riflette il suo controllo della società di gestione, oltre a 100.000 azioni detenute direttamente e ad altre azioni detenute congiuntamente. La comunicazione è presentata ai sensi della Regola 13d-1(b), indicando che queste partecipazioni sono dichiarate come passive e non hanno lo scopo di modificare o influenzare il controllo dell'emittente. La documentazione include un accordo di deposito congiunto e l'indirizzo commerciale delle persone che presentano la segnalazione.
Neogenomics, Inc. — El Schedule 13G revela que First Light Asset Management, LLC posee de forma beneficiaria 9.544.749 acciones de acciones ordinarias de Neogenomics (aproximadamente 7,39% de la clase). Mathew P. Arens figura como propietario beneficiario de 9.784.749 acciones (aproximadamente 7,57%), cifra que refleja su control sobre el gestor además de 100.000 acciones que posee directamente y otras acciones en tenencia conjunta. La presentación se realiza conforme a la Regla 13d-1(b), lo que indica que estas participaciones se declaran como pasivas y no buscan cambiar ni influir en el control del emisor. El documento incluye un acuerdo de presentación conjunta e identifica la dirección comercial de las personas informantes.
Neogenomics, Inc. — Schedule 13G에 따르면 First Light Asset Management, LLC는 Neogenomics 보통주 9,544,749주를 실질적 보유자로 보유하고 있으며(해당 등급의 약 7.39%), Mathew P. Arens는 실질적 보유주식 9,784,749주(약 7.57%)로 보고됩니다. 이 수치는 그가 매니저에 대한 통제권을 보유하고 있음을 반영하며, 여기에 직접 보유한 100,000주와 공동 보유한 추가 주식이 포함됩니다. 해당 보고서는 Rule 13d-1(b)에 따라 제출되어 이러한 보유가 수동적(passive)으로 신고되었으며 발행인의 지배권을 변경하거나 영향력을 행사하려는 의도가 아님을 명시합니다. 제출서류에는 공동 제출 합의서와 보고인의 사업장 주소가 포함되어 있습니다.
Neogenomics, Inc. — Le Schedule 13G indique que First Light Asset Management, LLC détient à titre bénéficiaire 9 544 749 actions ordinaires de Neogenomics (environ 7,39% de la catégorie). Mathew P. Arens est déclaré propriétaire bénéficiaire de 9 784 749 actions (environ 7,57%), montant reflétant son contrôle du gestionnaire ainsi que 100 000 actions détenues directement et d'autres actions détenues conjointement. Le dépôt est effectué en vertu de la Rule 13d-1(b), indiquant que ces participations sont déclarées comme passives et n'ont pas pour objet de changer ou d'influencer le contrôle de l'émetteur. Le dossier comprend un accord de dépôt conjoint et l'adresse professionnelle des personnes déclarante.
Neogenomics, Inc. — Das Schedule 13G legt offen, dass First Light Asset Management, LLC wirtschaftlich 9.544.749 Aktien der Stammaktien von Neogenomics hält (etwa 7,39% der Klasse). Mathew P. Arens wird als wirtschaftlicher Eigentümer von 9.784.749 Aktien (etwa 7,57%) ausgewiesen; diese Zahl spiegelt seine Kontrolle über den Manager sowie 100.000 Aktien in direktem Besitz und weitere gemeinsam gehaltene Aktien wider. Die Einreichung erfolgt nach Rule 13d-1(b), was anzeigt, dass diese Beteiligungen als passiv gemeldet werden und nicht darauf abzielen, die Kontrolle über den Emittenten zu ändern oder zu beeinflussen. Die Akte enthält eine gemeinsame Einreichungsvereinbarung und nennt die Geschäftsadresse der meldenden Personen.
- Significant disclosed stake: First Light Asset Management holds 9,544,749 shares (7.39%), which is a meaningful minority position
- Controller disclosure: Mathew P. Arens is reported with 9,784,749 shares (7.57%), clarifying beneficial ownership and control relationships
- Filed as passive: Reported under Rule 13d-1(b), indicating holdings are stated as held in the ordinary course and not for control
- None.
Insights
TL;DR: A passive investor and its controlling individual report just over 7% ownership each, a meaningful minority stake but not an activist position.
First Light Asset Management reports beneficial ownership of 9,544,749 shares (7.39%), while Mathew P. Arens is reported at 9,784,749 shares (7.57%). The Schedule 13G was filed under Rule 13d-1(b), which signals the positions are held in the ordinary course of business and not for control purposes. For investors, a >5% passive stake is material because it signals a substantial, visible shareholder, yet the classification as passive reduces near-term governance change risk. No transaction amounts, purchase dates, or voting changes are disclosed.
TL;DR: Reported holdings represent a significant minority interest but are explicitly characterized as non-control, limiting immediate governance implications.
The filing identifies First Light as advisor to accounts and funds holding 9,544,749 shares, and Mr. Arens as controller of the manager plus direct and joint holdings totaling 9,784,749 shares. TheSchedule 13G classification under Rule 13d-1(b) means the reporting parties certify the shares are not held to influence control. This reduces the likelihood of imminent board or strategic demands, though investors should note the size of the stake when assessing shareholder composition. The filing provides no indications of planned activism or board nominations.
Neogenomics, Inc. — Il Schedule 13G riporta che First Light Asset Management, LLC detiene in via beneficiaria 9.544.749 azioni del capitale sociale ordinario di Neogenomics (circa 7,39% della classe). Mathew P. Arens risulta titolare beneficiario di 9.784.749 azioni (circa 7,57%), cifra che riflette il suo controllo della società di gestione, oltre a 100.000 azioni detenute direttamente e ad altre azioni detenute congiuntamente. La comunicazione è presentata ai sensi della Regola 13d-1(b), indicando che queste partecipazioni sono dichiarate come passive e non hanno lo scopo di modificare o influenzare il controllo dell'emittente. La documentazione include un accordo di deposito congiunto e l'indirizzo commerciale delle persone che presentano la segnalazione.
Neogenomics, Inc. — El Schedule 13G revela que First Light Asset Management, LLC posee de forma beneficiaria 9.544.749 acciones de acciones ordinarias de Neogenomics (aproximadamente 7,39% de la clase). Mathew P. Arens figura como propietario beneficiario de 9.784.749 acciones (aproximadamente 7,57%), cifra que refleja su control sobre el gestor además de 100.000 acciones que posee directamente y otras acciones en tenencia conjunta. La presentación se realiza conforme a la Regla 13d-1(b), lo que indica que estas participaciones se declaran como pasivas y no buscan cambiar ni influir en el control del emisor. El documento incluye un acuerdo de presentación conjunta e identifica la dirección comercial de las personas informantes.
Neogenomics, Inc. — Schedule 13G에 따르면 First Light Asset Management, LLC는 Neogenomics 보통주 9,544,749주를 실질적 보유자로 보유하고 있으며(해당 등급의 약 7.39%), Mathew P. Arens는 실질적 보유주식 9,784,749주(약 7.57%)로 보고됩니다. 이 수치는 그가 매니저에 대한 통제권을 보유하고 있음을 반영하며, 여기에 직접 보유한 100,000주와 공동 보유한 추가 주식이 포함됩니다. 해당 보고서는 Rule 13d-1(b)에 따라 제출되어 이러한 보유가 수동적(passive)으로 신고되었으며 발행인의 지배권을 변경하거나 영향력을 행사하려는 의도가 아님을 명시합니다. 제출서류에는 공동 제출 합의서와 보고인의 사업장 주소가 포함되어 있습니다.
Neogenomics, Inc. — Le Schedule 13G indique que First Light Asset Management, LLC détient à titre bénéficiaire 9 544 749 actions ordinaires de Neogenomics (environ 7,39% de la catégorie). Mathew P. Arens est déclaré propriétaire bénéficiaire de 9 784 749 actions (environ 7,57%), montant reflétant son contrôle du gestionnaire ainsi que 100 000 actions détenues directement et d'autres actions détenues conjointement. Le dépôt est effectué en vertu de la Rule 13d-1(b), indiquant que ces participations sont déclarées comme passives et n'ont pas pour objet de changer ou d'influencer le contrôle de l'émetteur. Le dossier comprend un accord de dépôt conjoint et l'adresse professionnelle des personnes déclarante.
Neogenomics, Inc. — Das Schedule 13G legt offen, dass First Light Asset Management, LLC wirtschaftlich 9.544.749 Aktien der Stammaktien von Neogenomics hält (etwa 7,39% der Klasse). Mathew P. Arens wird als wirtschaftlicher Eigentümer von 9.784.749 Aktien (etwa 7,57%) ausgewiesen; diese Zahl spiegelt seine Kontrolle über den Manager sowie 100.000 Aktien in direktem Besitz und weitere gemeinsam gehaltene Aktien wider. Die Einreichung erfolgt nach Rule 13d-1(b), was anzeigt, dass diese Beteiligungen als passiv gemeldet werden und nicht darauf abzielen, die Kontrolle über den Emittenten zu ändern oder zu beeinflussen. Die Akte enthält eine gemeinsame Einreichungsvereinbarung und nennt die Geschäftsadresse der meldenden Personen.